糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

ADA 2014：**奖授予GLP-1研究领域奠基人

2014-06-18 王娣 发自ADA现场 中国医学论坛报CMT糖尿病微信

GLP-1研究领域ADA班廷奖
关注

班廷(Banting)奖是ADA年会的最高荣誉。在ADA 2014主席演讲结束后，本年度班廷(Banting)奖章获得者也进行了精彩演讲。今年的班廷(Banting)奖授予了胰高血糖素样肽(GLP)-1研究领域的奠基人和领袖之一、加拿大多伦多大学的德鲁克(Daniel Drucker)教授。  ADA 2014班廷奖获得者Daniel Drucker教授作演讲 早在1987年，D

班廷(Banting)奖是ADA年会的最高荣誉。在ADA 2014主席演讲结束后，本年度班廷(Banting)奖章获得者也进行了精彩演讲。今年的班廷(Banting)奖授予了胰高血糖素样肽(GLP)-1研究领域的奠基人和领袖之一、加拿大多伦多大学的德鲁克(Daniel Drucker)教授。

 ADA 2014班廷奖获得者Daniel Drucker教授作演讲

早在1987年，Drucker就观察到GLP-1(7-37)在培养的胰岛素瘤细胞中促进了胰岛素释放，进而推测其“可能是胰岛素基因表达的生理调节者”，由此开始了他专注于肠道激素的研究生涯。二十余年来，他获得了29项美国专利，他的科研成果引发了糖尿病治疗史上的一场革命，直接孕育和孵化了GLP-1受体激动剂、DPP-4抑制剂以及替度鲁肽(重组人GLP-2，首个用于依赖肠外营养的短肠综合征患者长期治疗的药物)三类药物，这种丰富和直接的转化医学成果使全球不计其数的患者获益。

凭借在肠道激素领域的开创性成就，他获得2012年欧洲糖尿病研究学会(EASD)Claude Bernard奖，此番又问鼎ADA颁发的最高科学成就奖。6月15日，Drucker以《解码肠道代谢信息，推动治疗革新》为题致获奖演说。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=22954, encodeId=8c09229540b, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 16:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20765, encodeId=ef8c20e6509, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264510, encodeId=389a1264510a3, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422686, encodeId=07311422686fb, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=)]
    2015-05-08 qingfengqishi5

    不错哦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=22954, encodeId=8c09229540b, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 16:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20765, encodeId=ef8c20e6509, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264510, encodeId=389a1264510a3, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422686, encodeId=07311422686fb, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=)]
    2015-04-11 x35042875

    国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=22954, encodeId=8c09229540b, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 16:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20765, encodeId=ef8c20e6509, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264510, encodeId=389a1264510a3, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422686, encodeId=07311422686fb, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=)]
    2014-06-20 医者仁心

    #ADA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=22954, encodeId=8c09229540b, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Fri May 08 16:08:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20765, encodeId=ef8c20e6509, content=国真实妊娠糖尿病患病率应该在这两种方案得到的患病率之间, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:42:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264510, encodeId=389a1264510a3, content=<a href='/topic/show?id=150f19229c' target=_blank style='color:#2F92EE;'>#ADA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1922, encryptionId=150f19229c, topicName=ADA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422686, encodeId=07311422686fb, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8077, encryptionId=54fa80e701, topicName=GLP-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8f23732777, createdName=yibei, createdTime=Fri Jun 20 01:33:00 CST 2014, time=2014-06-20, status=1, ipAttribution=)]
    2014-06-20 yibei

    #GLP-1#

    0